brookhaven-lab

36 Days Until Stephen Goldner Explores Life After Legalization

Sponsored Content provided by Marijuana Investor Summit

Stephen Goldner, a forensic toxicologist at Quantum 9, a cannabis consulting and technology firm, will be discussing life after legalization at the California Cannabis Business Expo in San Francisco this March.

Goldner started his career as a Supervisor Forensic Toxicologist at the Office of the Chief Medical Examiner, New York City. While in this position, Goldner and his team developed the first commercial laboratory chromatography tests for drugs. His pioneering work helped launch the drug screening industry in the 1970s. Goldner, along with his mentor John Broich from Brookhaven Labs, then went on to formulate the drug called “methadone,” including getting it approved by the FDA.  Goldner and Broich also developed lab procedures to detect LSD, cannabis, and other drugs in a person’s body.  

With his rich knowledge of toxicology, you won’t want to miss Goldner’s discussion on life after legalization and what it means for the regulatory landscape.

The California Cannabis Business Expo follows MJIC Media’s inaugural event, the Marijuana Investor Summit in Denver in April 2014, which drew more than 1,000 people and 100 exhibitors. The California Cannabis Business Expo in San Francisco is a unique opportunity to learn about the state of cannabis in California directly from those shaping the legal landscape.

Tickets to the California Cannabis Business Expo in San Francisco can be purchased online.

The post 36 Days Until Stephen Goldner Explores Life After Legalization appeared first on MJI News.



Read more from MJI News http://ift.tt/1PTtoih

Hot liquid cultures of algae look really cool, right? Brookhaven biologists Crysten and Ian Blaby use this setup to explore the many genes that play a role in a plant’s ability to harness energy and what those genes could mean for enhancing bioenergy crops.

They grow hundreds of thousands of algae samples with mutant genes simultaneously to see which grow better in response to different conditions—such as temperature, light, and nutrient availability.

“Because of the simplicity and fast growth rates of single-celled algae relative to other plants, experiments can be performed at a greater pace. It is also easier to manipulate them and change their growing conditions,” said Ian. “Additionally, they take up much less space than land plants, making algae the perfect model system for our gene-focused research.”

The two are using the alga to study the function of plant genes. “We have a good idea of the function of five to 10 percent of plant genes and can make an estimated guess for the function of 30 to 40 percent,” said Ian. “But, the function of the other remaining 40 to 50 percent is unknown.”

Crysten’s research focuses on the genes that regulate the level of metal in cells and how organisms take up metal from the environment. Ian’s expertise is in plant metabolism. He is looking at photosynthesis and subsequent carbon usage—how plants create energy from sunlight, carbon dioxide (CO2), and water. With their research, we are taking steps towards understanding plant biology and building better biofuels.  

motherboard.vice.com
Two American Physics Labs Are Vying for a Billion-Dollar Particle Accelerator

Two labs are vying for government funding to host a billion-dollar atom smasher, and the battle is getting political. The Relativistic Heavy Ion Collider (RHIC) at Brookhaven National Lab in Brookhaven, New York lies in a circular underground tunnel over two miles in circumference. via Pocket

Footage of first Parkinson’s treatments found after 50 years – New Scientist

Videos just discovered show the first people ever to be treated for the symptoms of Parkinson’s disease. The footage, hidden for half a century, shows Chilean miners with severe movement problems improving on daily doses of L-dopa.

The videos were filmed by George Cotzias at Brookhaven National Laboratory in Upton, New York. In 1963, while studying the toxic effects of manganese in human tissues, Cotzias learned of four workers in the Corral del Quemado mine in Andacollo, Chile, who had developed a syndrome called manganism – which resembled Parkinson’s – through inhaling manganese dust.

Cotzias travelled to Chile to include the miners in a trial of leva-dopa, a chemical building block that the body converts into dopamine, low levels of which cause uncontrolled movements in people with Parkinson’s. L-dopa was being tested in Parkinson’s patients around the same time but with little success – even small amounts caused adverse side-effects that prevented a high enough dose reaching the brain.

The footage clearly shows the severe problems with walking and turning miners had before treatment. After several months of receiving a daily dose of L-dopa, they were able to feed themselves, shave, tie their shoelaces, and run.

This is our own George Cotzias’s research. He was part of a 1960s Brookhaven program that used radioisotopes to study the relationship between trace elements and neurological diseases. Parkinson’s disease is a degenerative brain disorder causing trembling limbs and sometimes incapacity. Early on, Brookhaven studies showed L-dopa treatments resulted in relief of symptoms in mild cases of the disease and striking improvements in patients with moderately advanced cases. Dr. Cotzias took this video himself, while testing the effects of L-dopa on miners affected by overexposure to manganese. Even all these years later, L-dopa remains the “gold standard” for treating Parkinson’s.